Atlanta, Georgia, USA (September 28, 2021) – Hamilton Company and Rhinostics, an early-stage Harvard University spin-off, are combining their respective strengths to improve the speed and quality of nasal specimen workflows and nasopharyngeal, from collection to processing while also reducing the need for active workforce involvement. This type of sample is widely used to detect antibodies and antigens related to novel coronavirus, SARS-CoV-2 and many other pathogens.
Hands-free automated workflow includes use of the RHINOstic™ nasal swab collection device and one of Hamilton’s Microlab® STAR™, Microlab NIMBUS® or Microlab Prep™ automated liquid handling workstations, as well than the LabElite® DeCapper from Hamilton Storage Technologies. This combination of technologies alleviates common bottlenecks in testing workflows, even during periods of sample influx. By increasing sample throughput and reducing turnaround times, stakeholders are empowered and informed to make confident downstream decisions regarding patient treatment strategies.
The patent-pending RHINOstic nasal and buccal swab collection device consists of a polypropylene swab stick, embedded in an automation-compatible cap, and a code-labeled transport tube – two-dimensional bars (2D). At the point of collection, the swab minimizes patient discomfort during sample collection. Specimens collected via the RHINOstic can be shipped without the use of viral transport medium (VTM) to reduce reagent costs and the risk of leakage or creation of aerosols. The absence of VTM also eliminates the need to concentrate samples prior to analysis.
Up to 96 samples can be automatically added and decapped at a time using the LabElite DeCapper with a 12-channel head and conversion kit. The LabElite DeCapper can be used as a stand-alone device or integrated with Hamilton’s automated liquid handlers.
Hamilton’s automated liquid handlers consistently and automatically perform tedious and time-consuming pipetting and other tasks so users can take care of more valuable tasks. By reducing active working time, efficiency and productivity are increased throughout the laboratory. Autonomous operation also reduces the risk of user exposure to biohazards.
Each Hamilton automated liquid handler can be optimized with tools and methods programmed for the application at hand, including PCR, next-generation sequencing (NGS), ELISA and more. User-friendly software guides any user through test setup and processing, and when used with Hamilton pipette tips, patented CO-RE® (Compressed O-Ring Expansion) technology creates a tight seal between pipetting chuck and tip for highly accurate and consistent results.
Automated sample processing using this hands-free automated workflow from Hamilton and Rhinostics can be easily scaled up at any time without increasing labor, equipment, or reagent costs.
About Hamilton Company: Hamilton Company is a global company with subsidiaries in Reno, Nevada; Franklin, Massachusetts (both in the United States); and Bonaduz, Switzerland and sales offices worldwide. Hamilton Company and its affiliated entities are an industry leader in the design and manufacture of liquid handling, process analytics, robotics and automated storage solutions. For over 60 years, Hamilton Company has met customer needs by combining quality materials with skilled craftsmanship to ensure the highest level of performance. Hamilton Company’s ongoing commitment to precision and quality has earned us ISO 9001 global certification. For more information, visit www.hamiltoncompany.com.
About Rhinostics: Rhinostics Inc. is a start-up company that markets a simple and elegant solution to bring efficiency and cost reduction to the laboratory workflow. The RHINOstic Nasal Swab offers features that increase sample throughput by more than 10 times while removing labor and errors from the laboratory workflow. The swab is integrated on a cap which can be automated for removal from the tube while all 96 samples are simultaneously accessed by scanning a 2D barcode at the bottom of the tubes. Additionally, the device allows dry shipping of respiratory specimens without viral transport media, and nasal collection allows for easy and comfortable collection. Viral samples can be released directly into a small amount of saline, providing a sample concentration of 30x or more, providing greater standardization and improving downstream assay reliability. The product offers an immediate impact on increasing the efficiency of COVID testing while being applicable to broader viral, bacterial, and genetic respiratory testing using polymerase chain reaction (PCR) and next-generation sequencing (NGS) ). The RHINOstic product is registered as a Class I Exempt Medical Device with the FDA and is available for purchase. To learn more, visit https://www.rhinostics.com.
All trademarks are owned and/or registered by Hamilton Company or Rhinostics in the United States and/or other countries. For more details, visit www.hamiltoncompany.com/trademarks or www.rhinostics.com.
Please send reader inquiries regarding this release directly to [email protected] Where [email protected]